Leadership

Board of Directors

President and Director

John A. Taylor III, MD, MS, is a urologic oncologist whose practice and research are focused on bladder cancer. He received his medical degree from Columbia University where he also did his urological training.

He obtained a masters degree in Clinical & Translational Science from the University of Connecticut. His work has been funded by the American Cancer Society, American Urological Association, American Geriatrics Society and the Connecticut Institute for Clinical and Translational Science.

Gene Pranzo, Esq.,

Gene Pranz is the trustee for The Albert Charitable Trust and CEO and president of The Dorothy R. Havemeyer Foundation.

He was instrumental in developing the Foundation from its inception in 1979 to its role in scientific research, workshops and publications.

Carolyn D. Runowicz, MD

Carolyn D. Runowicz is currently the Executive Associate Dean for Academic Affairs at the Herbert Wertheim College of Medicine of Florida International University.
She was the first women president of the Society of Gynecology-Oncology and is a past president of the American Cancer Society. She has served on the National Cancer Advisory Board (appointed by President Bush) and was chair for four years. She is currently on the Board of Directors of the American Society of Clinical Oncology and serves on multiple scientific advisory boards including the NCI.

Dr. Molly Ingersoll

Dr. Molly Ingersoll received her PhD studying host-pathogen interactions from NYU School of Medicine working with Arturo Zychlinsky at NYU and at the Max Planck Institute for Infection Biology in Berlin, Germany.
A brief postdoctoral fellowship at Washington University School of Medicine, in St Louis, MO with Scott Hultgren, studying innate immunity to urinary tract infection was followed by a postdoctoral appointment at Mount Sinai Medical Center in NYC, investigating monocyte and dendritic cell biology. Dr. Ingersoll is a Research Director with joint appointment between Institut Cochin and Institut Pasteur in Paris. Her team studies mucosal immunity in the bladder in the context of infection and cancer – to understand how this tissue responds to infectious and non-infection inflammatory diseases and to develop immunomodulatory approaches to improve disease outcomes.

Thomas Flaig, MD

Thomas Flaig, MD, is a medical oncologist and has been part of the University of Colorado since 2003, when he started as an oncology fellow. He has held a variety of administrative roles on campus, including in the School of Medicine,
cancer center and UCHealth. He is currently the vice chancellor for research for the CU Denver | CU Anschutz Medical Campus since March of 2020.In addition to his clinical care and administrative work, Dr. Flaig has significant clinical and translational research experience, having led both local and national multi-center clinical trials and served as the local principal investigator on a large number of clinical trials including Phase I, II and III studies. He also runs a translational lab focused on therapeutic and biomarker development in urologic cancers. Dr. Flaig is a member of the National Cancer Institute’s bladder cancer task force. He also serves as chair of the National Comprehensive Care Network (NCCN) bladder cancer committee and as the Co-Chair of the National Clinical Trial Network (NCTN) SWOG Bladder Committee

Scientific Advisory Board

The SAB includes respected members of the bladder cancer community to include; one genitourinary oncologist, one urologic oncologist and one basic scientist with focus on bladder cancer. The SAB is responsible for directing the scientific content of the annual symposium, appointing the annual symposium steering committee, and reviewing competitive applications for potential funding and Albert Institute summer fellow positions.

Dr. Badrinath

Dr. Badrinath Konety serves as CEO of University of Minnesota Physicians as well as Vice Dean for Clinical Affairs at the University of Minnesota Medical School.
He is also a professor in the Department of Urology and Director of the Institute for Prostate and Urologic Cancers. Dr. Konety is a fellow of the American College of Surgeons and the American Urologic Association. He also is secretary/treasurer of the Societe Internationale d’Urologie (US Section).  He is on the editorial board of several journals and is a member of multiple guideline panels. He has been awarded a number of grants from the DOD, NCI, ACS and CDC. He is recognized as an expert on prostate and bladder cancer. He has given presentations on a wide range of urologic oncology topics nationally and internationally. He has been listed on the Best Doctors in America since 2009.

Matthew I. Milowsky, MD, FASCO

Matthew Milowsky is the George Gabriel and Frances Gable Villere Distinguished Professor of Bladder and Genitourinary Cancer Research, Vice Chief for Research & Education,

He is also a professor in the Department of Urology and Director of the Institute for Prostate and Urologic Cancers. Dr. Konety is a fellow of the American College of Surgeons and the American Urologic Association. He also is secretary/treasurer of the Societe Internationale d’Urologie (US Section).  He is on the editorial board of several journals and is a member of multiple guideline panels. He has been awarded a number of grants from the DOD, NCI, ACS and CDC. He is recognized as an expert on prostate and bladder cancer. He has given presentations on a wide range of urologic oncology topics nationally and internationally. He has been listed on the Best Doctors in America since 2009.

Resources

Get Connected

American Cancer Society
National Cancer Institute
Bladder Cancer Advocacy Network